Radiotherapy dose escalation in locally advanced NSCLC – the limits of conventional radiochemotherapy

Until today, overall survival remains poor in locally advanced stage III NSCLC, and progress observed in historical comparisons is probably to a large extent the result of improved patient staging using FDG-PET and endoscopic nodal staging. Recent strategies such as the use of maintenance chemotherapy, addition of targeted therapy (e.g. cetuximab) and newer chemotherapy agents such as pemetrexed or tumor vaccines all failed to increase survival. Additionally, studies have not demonstrated the superiority of trimodality over bimodality treatment.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Tags: Editorial Source Type: research